Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
IDEAYA Biosciences, Inc. logo

NASDAQ · IDYA

IDEAYA Biosciences, Inc.

Healthcare · Biotechnology

$31.96

Down-$0.93 (-2.83%)

Updated Oct 31, 2026, 3:47 AM

SID Score

4.0/10

Composite research score

Smart Money

58/100

Neutral

Market cap
2.94B
P/E ratio
-8.97
Dividend yield
0.00%
52-week range
$26.81 – $42.68
Volume
838.03K
Avg. volume
1.13M

Price performance · IDYA

IDYA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

IDYA closed at $31.96 after 21 trading sessions, down 14.45% for the selected period.

Last close
$31.96
Period change
-14.45%
Period low
$31.96
Period high
$38.06
Daily close
View OHLC price history
IDYA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$32.76$33.50$31.70$31.96838.03K
Oct 29, 2026$33.95$34.51$32.76$32.891.62M
Oct 28, 2026$33.02$34.28$32.80$33.96994.24K
Oct 27, 2026$32.66$33.69$32.34$33.501M
Oct 26, 2026$35.31$35.31$32.52$32.881.19M
Oct 23, 2026$36.35$36.35$34.535$34.711.13M
Oct 22, 2026$35.02$36.20$35.02$36.12603.2K
Oct 21, 2026$35.43$36.11$35.33$35.47651.84K
Oct 20, 2026$33.93$35.63$33.735$35.36962.26K
Oct 19, 2026$33.33$34.11$32.80$33.81766.37K
Oct 16, 2026$33.965$33.97$32.72$32.85655.71K
Oct 15, 2026$34.24$34.67$33.62$33.851.34M
Oct 14, 2026$34.38$34.84$33.62$33.861.06M
Oct 13, 2026$36.06$36.20$34.25$34.261.03M
Oct 12, 2026$35.98$36.42$35.66$36.06441.48K
Oct 9, 2026$35.94$36.72$35.94$36.11699.09K
Oct 8, 2026$35.85$36.32$35.10$36.06548.73K
Oct 7, 2026$36.19$36.97$36.00$36.26552.06K
Oct 6, 2026$38.23$38.565$36.1111$36.63802.45K
Oct 5, 2026$37.57$38.26$37.04$38.06658.01K
Oct 2, 2026$38.52$38.54$37.00$37.36579.05K

Latest IDYA news

The latest Smart Investors Daily articles mentioning IDYA.

Stock researchCompany · Overview

IDYA research

Overview

Company profile and research snapshot.

Company profile

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$42.43
Implied upside
—
Analysts
—
IDYA recent ratings
DateFirmRatingTarget
Oct 16, 2026William BlairOutperform—
Oct 14, 2026StifelBuy—
Sep 9, 2026GuggenheimBuy—
Sep 1, 2026CitizensMarket Outperform—
Aug 5, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced updated clinical results that show promising anti-tumor activity and preliminary overall survival results for IDE849 (SHR-4849), its investigational antibody-drug conjugate (ADC) directed against delta-like ligand 3 (DLL3) and carrying a topoisomerase I (TOP1) inhibitor payload. IDEAYA's partner, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), is presenting the results from its Phase 1 study in China in relapsed small cell lung cancer

Yahoo · Oct 19, 2026

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced updated clinical data from three ongoing studies evaluating darovasertib in metastatic and primary uveal melanoma (UM) that will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place on October 23–27 in Madrid, Spain. The updates will include Phase 2 expansion data from OptimUM-01 in HLA-A*02:01-positive patients with metastatic uveal melanoma (mUM), subg

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By